U.S. pharmaceuticals company Johnson & Johnson (JNJ) said Tuesday it completed the tender offer for Dutch biotechnology company Crucell NV (CRXL.AE) and has declared the offer unconditional.

MAIN FACTS:

- Johnson & Johnson declares the Offer for unconditional

- As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

- Share Acceptance Level is 95.24% of the issued and outstanding share capital of Crucell

- Settlement of the Offer will take place on 25 February 2011

- Remaining Shares can be tendered in a Subsequent Offering Period ending 8 March 2011

- Johnson & Johnson intends to acquire the remaining Shares not tendered by means of buy-out proceedings in accordance with article 2:92a and/or 359c of the Dutch Civil Code, to be initiated as soon as reasonably practicable under applicable rules and regulations

- By Amsterdam Bureau, Dow Jones Newswires; amsterdam@dowjones.com
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Crucell NV ADS, Each Representing One Ordinary Share (MM) Charts.
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Crucell NV ADS, Each Representing One Ordinary Share (MM) Charts.